ESR1 and breast carcinoma: Furthermore, as highlighted by some recent studies, more efforts are needed to optimize PRSs for the prediction of estrogen receptor (ER) negative (ER−) breast cancer [22, 23], which is more aggressive and less common than estrogen receptor positive (ER+) breast cancer.